PureTech Health (LON: PRTC) has recently received a number of price target changes and ratings updates:

  • 9/9/2019 – PureTech Health had its “buy” rating reaffirmed by analysts at Peel Hunt.
  • 9/2/2019 – PureTech Health had its “buy” rating reaffirmed by analysts at Peel Hunt.
  • 8/27/2019 – PureTech Health had its price target raised by analysts at Liberum Capital from GBX 336 ($4.39) to GBX 347 ($4.53). They now have a “buy” rating on the stock.
  • 8/27/2019 – PureTech Health had its “buy” rating reaffirmed by analysts at Peel Hunt.
  • 8/1/2019 – PureTech Health had its “buy” rating reaffirmed by analysts at Peel Hunt.
  • 7/17/2019 – PureTech Health had its “buy” rating reaffirmed by analysts at Liberum Capital.
  • 7/17/2019 – PureTech Health had its “buy” rating reaffirmed by analysts at Peel Hunt. They now have a GBX 380 ($4.97) price target on the stock, up previously from GBX 344 ($4.49).

PRTC stock traded up GBX 12 ($0.16) during trading on Friday, hitting GBX 290 ($3.79). 53,389 shares of the company’s stock were exchanged, compared to its average volume of 71,917. The business has a 50-day moving average price of GBX 279.53 and a two-hundred day moving average price of GBX 218.89. The stock has a market capitalization of $785.67 million and a price-to-earnings ratio of -103.57. PureTech Health plc has a 52-week low of GBX 152 ($1.99) and a 52-week high of GBX 307 ($4.01). The company has a current ratio of 0.69, a quick ratio of 0.67 and a debt-to-equity ratio of 31.14.

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.

Featured Story: Buyback

Receive News & Ratings for PureTech Health plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health plc and related companies with MarketBeat.com's FREE daily email newsletter.